The controversy began with a series of three studies pointing to ITSN1 as a Parkinson’s disease susceptibility gene. Loss-of-function variants are mutations that disable a gene’s protein product, and when such variants occur in ITSN1, the resulting condition is predicted to be haploinsufficiency: having only one working copy of the gene is not enough for normal cellular function. The most recent and most compelling piece of evidence came from Ganoza and colleagues, who screened the Rostock International Parkinson’s Disease study, known as ROPAD, a cohort that includes 8,660 participants with Parkinson’s disease. Their analysis globally replicated the earlier findings and established that ITSN1 loss-of-function carriers represent roughly one to two individuals per thousand with Parkinson’s disease suspected of having a genetic cause.

The scale of the risk elevation is what makes ITSN1 so remarkable. According to the reply, a carrier of an ITSN1 loss-of-function variant faces between five and fifteen times the risk of developing Parkinson’s disease compared with a non-carrier. That places ITSN1 among the strongest genetic risk factors identified for the condition, in a category typically reserved for well-known genes such as LRRK2 and GBA1. Equally notable is the clinical picture: the Parkinson’s disease that emerges in ITSN1 carriers does not differ significantly from classical, non-genetic Parkinson’s disease, meaning carriers present with the familiar motor syndrome rather than an exotic or easily distinguishable variant of the illness.

The Paris team had approached the gene from a different angle. After identifying three pedigrees with ITSN1 loss-of-function variants in their own cohort at the Paris Brain Institute, two of which showed positive segregation of the variant with disease across generations, they hypothesized that ITSN1 might act as a Mendelian gene. In genetics, a Mendelian gene is one in which a single mutation is sufficient to cause disease in a predictable inheritance pattern, typically autosomal dominant or recessive, as opposed to risk genes that merely shift probabilities. If ITSN1 were Mendelian, families carrying one mutation would show the disease appearing in multiple relatives in an orderly pattern, and genetic counseling would follow established rules for dominant disorders.

Ganoza and colleagues tested this hypothesis using the ROPAD data and found it wanting. The frequency of positive family history among ITSN1-associated Parkinson’s disease individuals did not differ significantly from that of individuals without ITSN1 loss-of-function variants: 23 percent versus 34 percent, a difference that failed to reach statistical significance with a p-value of 0.5. On its face, this argues against a straightforward Mendelian model, since a true dominant gene should produce a conspicuously elevated rate of affected relatives. But the Paris group, in their reply, argues that the comparison is less conclusive than it appears, and they raise two methodological concerns that deserve careful attention from anyone following the genetics of neurodegenerative disease.

The first concern involves the composition of the ROPAD cohort itself. The Paris researchers noticed that the frequency of positive family history among non-carriers, 34 percent, seems higher than what would be expected for classical Parkinson’s disease in the general population. The likely explanation, they suggest, is recruitment bias: the cohort was enriched for individuals already suspected of having a genetic etiology for their disease. The authors of the original analysis acknowledged as much, noting that the early average age at onset in their cohort, 55 years, supports the presence of such a bias. Age at onset is a classic marker in Parkinson’s genetics, since earlier-onset disease is more often genetically driven, and a cohort selected for early onset will naturally over-represent familial cases on both sides of any genetic comparison.

The second concern is more fundamental: the ROPAD analysis did not provide pedigrees, or familial structures, for the 13 individuals carrying ITSN1 loss-of-function variants. Without those family trees, the field cannot know how many relatives were actually affected in individuals reporting a positive family history, whether the inheritance pattern suggested autosomal dominance or recessivity, or whether segregation analysis was performed to confirm that the variant tracked with disease. The Paris team offers a plausible alternative explanation for the negative result: several of the loss-of-function variants may have arisen de novo, meaning spontaneously in the carrier rather than being inherited, which would explain why family history was not always positive. There is also growing evidence of reduced penetrance for ITSN1, meaning that not everyone who carries a damaging variant develops disease. Sorting out these possibilities, the reply argues, will be essential before any conclusion can be drawn about the Mendelian hypothesis, and before accurate genetic counseling can be offered to carriers and their relatives.

The counseling challenge is compounded by a feature that makes ITSN1 genuinely unusual among Parkinson’s genes. Loss-of-function variants in ITSN1 are associated not only with Parkinson’s disease but also with neurodevelopmental disorders, conditions that manifest in infancy or childhood. Other recently discovered genes, such as PSMF1 and EPG5, similarly produce a clinical spectrum running from early-onset neurodevelopmental disorders to later-onset Parkinsonism, but in those cases the type of variant usually differs, with truncating variants producing more severe phenotypic consequences than missense variants, which change only a single amino acid. For ITSN1, by contrast, only loss-of-function variants have been reported in Parkinson’s disease, and all are predicted to cause haploinsufficiency. That raises a puzzle the reply states plainly: why could the same mechanism, the loss of one functional copy of the gene, lead to two such distinct phenotypes, a childhood neurodevelopmental disorder in some carriers and a late-life neurodegenerative disease in others?

One hypothesis involves the protein itself. Two isoforms of the ITSN1 protein product, Intersectin-1, are currently known, and the location of a loss-of-function variant, whether it disrupts one isoform or both, could in principle explain the variable expressivity. However, the reply notes that variants identified in both diseases appear to affect both isoforms, so this explanation alone does not suffice, and, as Ganoza and colleagues hypothesized, other modifying factors remain to be discovered. The Paris team sketches several research strategies to find them. Functional studies using biological materials from ITSN1 loss-of-function carriers are already underway to clarify why the loss of Intersectin-1 predisposes to Parkinson’s disease, a question that persists even though the protein’s many roles, particularly as a scaffold for membrane-associated processes such as endocytosis, have been extensively characterized. A second approach would leverage large Parkinson’s disease datasets to compare genetic variant frequencies, environmental exposures, and lifestyle habits between unaffected elderly controls and carriers, with particular attention to ITSN2, the gene encoding the second member of the intersectin family, whose protein can compensate for some defects caused by reduced ITSN1 expression. The consistency of the average age at onset across studies should help researchers choose an appropriate inclusion age for controls. Beyond loss-of-function variants, certain missense variants in the missense-constrained region of the gene, spanning amino acids 1199 to 1722, have been linked to neurodevelopmental disorders, and their possible role in Parkinson’s disease has not yet been explored.

Why does this academic debate matter beyond the laboratory? The reply closes with a warning about clinical practice. Genetic testing is becoming more accessible, and ITSN1 loss-of-function variants are not so rare, so they will increasingly surface as incidental findings in people tested for unrelated reasons. For a neurologically unaffected adult, the counseling challenge resembles that of a pathogenic LRRK2 or severe GBA1 variant, both of which carry elevated risk with incomplete penetrance. But prenatal detection is a different matter entirely. A carrier fetus could face a neurodevelopmental disorder, Parkinson’s disease in later life, or possibly no ITSN1-related neurological disorder at all, a range of outcomes so wide and so uncertain that it could make decisions about pregnancy continuation agonizing for prospective parents. Having confirmed the association between ITSN1 and Parkinson’s disease through the ROPAD replication, the Paris team argues that the field now faces an urgent need to resolve the questions of penetrance, expressivity, and inheritance pattern, not only to advance the science of neurodegeneration but to give families the accurate, honest information they will inevitably demand as this gene enters routine clinical testing.

Subject of Research: Association between ITSN1 loss-of-function variants and Parkinson's disease risk and inheritance

Article Title: Reply to: Data from the ROPAD study corroborate an association between ITSN1 loss-of-function variants and Parkinson’s disease

Article References: Cogan, G., Tesson, C., Welment, L., Clot, F., LeGuern, E., Lanore, A., Dürr, A., Cormier-Dequaire, F., Debilly, B., Planes, M., Mangone, G., Lesage, S., & Brice, A. (2026). Reply to: Data from the ROPAD study corroborate an association between ITSN1 loss-of-function variants and Parkinson’s disease. npj Parkinson's Disease, 12(1), Article 236. https://doi.org/10.1038/s41531-026-01470-0

Image Credits: AI Generated

DOI: 10.1038/s41531-026-01470-0

Keywords: Parkinson's disease, ITSN1, genetics, loss-of-function variants, ROPAD study, haploinsufficiency, neurodevelopmental disorders, genetic counseling, reduced penetrance, Mendelian inheritance, LRRK2, GBA1

The story began to unfold in recent years when large-scale genetic studies pointed an unexpected finger at ITSN1. One analysis combining the deCODE, UK Biobank, and Accelerating Medicines Partnership Parkinson’s Disease datasets found that heterozygous loss-of-function variants in the gene, meaning changes that cripple one of the two inherited copies, confer a substantially elevated risk of Parkinson’s disease. A second study described five patients from three families carrying distinct frameshift variants in ITSN1, documenting their clinical pictures in detail. A third effort, drawing on the UK Biobank, the AMP-PD cohort, and the All of Us program, reported a similar increase in risk and even supplied functional evidence from a fruit fly model, showing that the protein encoded by ITSN1, called Intersectin-1, interacts with alpha-synuclein, the sticky protein that clumps in the brains of Parkinson’s patients. What remained unclear was whether patients carrying these variants show a recognizable clinical signature.

To answer that question, the ROPAD team turned to their own trove of data. They analyzed 8,660 reportedly unrelated Parkinson’s disease patients recruited between April 2019 and August 2024, drawn from Europe (68 percent), North America (16 percent), Israel (10 percent), Turkey (4 percent), and South America (2 percent). Crucially, all of these patients had undergone exome or genome sequencing and had no relevant variants in known Parkinson’s genes. That exclusion criterion matters: the researchers removed anyone carrying a pathogenic or likely pathogenic variant in dominant Parkinson’s genes such as LRRK2, SNCA, VPS35, RAB32, or CHCHD2, anyone with two heterozygous or one homozygous pathogenic variant in recessive genes including PARK7, PINK1, and PRKN, and anyone with a pathogenic or risk-factor variant in GBA1, the most common genetic contributor to the disease. By stripping out known genetic explanations, the team could ask whether ITSN1 variants stand on their own as a risk factor.

As a comparison group, the researchers examined 210,657 exome- or genome-sequenced individuals from the CENTOGENE Biodatabank, people referred for routine diagnostic testing, healthy parents in trio analyses, or participants in other observational studies, none of whom had been referred for or diagnosed with Parkinson’s disease. Loss-of-function variants were defined rigorously as start-loss, stop-gain, stop-loss, splice-donor, splice-acceptor, or frameshift changes, identified through a validated in-house bioinformatic pipeline. The team then mined electronic case report forms for clinical details, including year of birth, sex, age at disease onset, age at diagnosis, age at enrollment, family history, and motor scores from a partial Unified Parkinson’s Disease Rating Scale examination.

The result was striking. Thirteen of the 8,660 patients, or 0.15 percent, carried heterozygous loss-of-function variants in ITSN1, compared with just 0.025 percent of the 210,657 comparison individuals. That difference translates into an odds ratio of 6.09, with a 95 percent confidence interval of 3.31 to 11.19 and a p-value of 1.34 times ten to the minus six, a level of statistical significance that is difficult to dismiss. The allele-level comparison tells the same story: the proportion of ITSN1 loss-of-function alleles in the Parkinson’s patients, 0.075 percent, is roughly six times higher than the proportion found in non-Finnish European individuals in the Genome Aggregation Database, the reference catalog that population geneticists use as a baseline for how common variants should be. The enrichment held against every other population in that database as well.

Perhaps most convincing is how neatly these numbers overlap with the earlier studies. The confidence interval from the ROPAD analysis largely overlaps those reported in the two prior association studies, which found odds ratios of 7.3 and 10.5 respectively. The carrier frequency of 0.15 percent in ROPAD matches the 0.15 percent reported in the deCODE-led meta-analysis and the 0.14 percent in the family study. Within the ROPAD cohort itself, ITSN1 loss-of-function variants rank as the sixth most common disease-relevant genetic finding, trailing only variants in GBA1, LRRK2, PRKN, SNCA, and GCH1. For a gene that was essentially invisible to Parkinson’s researchers a few years ago, that is a rapid ascent.

Digging into the variants themselves, the team identified 12 distinct ITSN1 loss-of-function changes among the 13 patients: four nonsense mutations, six frameshift variants, and two splice site changes. Eleven of the twelve appeared only once, and one, a small deletion designated c.2842_2843del, was found in two patients. When the researchers tested whether those two German patients were related, analysis of extended haplotypes found no evidence of close relatedness or a shared founder chromosome, suggesting the variant arose independently in each case. This pattern of largely private, one-off mutations contrasts sharply with the genetics of other dominant Parkinson’s genes, where a handful of recurrent variants, such as the famous LRRK2 G2019S change, account for most cases. It also hints that the mutational spectrum of ITSN1 resembles that of genes where virtually any disruption of the protein is harmful.

There is an intriguing twist. More than 40 distinct ITSN1 loss-of-function variants have already been reported in individuals with autism and neurodevelopmental disorders, and four of the variants found in the ROPAD patients had appeared in that literature. This overlap raises the possibility of pleiotropy, the phenomenon in which a single gene produces different outcomes depending on context. Intersectin-1 is a scaffolding protein involved in clathrin-mediated endocytosis, synaptic vesicle recycling, and actin and CDC42-related signaling, processes essential both for building neural circuits during development and for maintaining them across a lifetime. Losing one functional copy, a state called haploinsufficiency, might disturb neurodevelopmental circuitry in childhood or undermine neuronal maintenance later in life. Which outcome prevails may depend on genetic modifiers, the residual expression produced by splice-altering variants, environmental stressors, and other factors scientists have yet to untangle.

On the clinical side, the ROPAD analysis found that patients carrying ITSN1 variants look, in most respects, like ordinary Parkinson’s patients. The male-to-female ratio, the proportion with a positive family history, the age at diagnosis, the age at enrollment, and the disease duration all failed to differ significantly between carriers and non-carriers. A multiple linear regression of motor scores adjusted for disease duration also found no significant difference, though the p-value of 0.075 leaves open the possibility of a subtle effect. Interestingly, the two earlier large-cohort studies did report significantly younger ages at onset among carriers, with mean or median onsets in the early sixties versus around seventy in non-carriers. The ROPAD cohort as a whole skews young, with a mean and median onset of 55 years, which likely explains why the same signal did not emerge here. Notably, the median onset of 53 years among ROPAD carriers is comparable to the 47-year average onset in the five family-study patients, and one ROPAD participant carried both an ITSN1 deletion and a mild GBA1 variant, a combination the researchers excluded from their main analysis because the GBA1 change may have modified her disease risk, echoing what has been documented in people carrying both LRRK2 and GBA1 variants.

Taken together, the findings cement ITSN1 as a genuine Parkinson’s disease gene, one that produces a form of the illness clinically indistinguishable from idiopathic disease. The authors propose the designation PARK-ITSN1 for this genetic entity and call for further research into its natural history and treatment responses, questions that will matter as genetic testing becomes routine and as pharmaceutical companies design trials stratified by genotype. The study also carries a broader lesson about the power of deeply curated clinical and genetic datasets: when a diagnostic laboratory pairs sequencing with systematic phenotyping across thousands of patients, even vanishingly rare risk factors, present in fewer than two people per thousand, can be detected, validated, and connected to the biology of one of the world’s most common neurodegenerative diseases.

Subject of Research: Association between ITSN1 loss-of-function variants and Parkinson's disease risk in the ROPAD cohort

Article Title: Data from the ROPAD study corroborate an association between ITSN1 loss-of-function variants and Parkinson’s disease

Article References: Ganoza, C. A., Westenberger, A., Paul, J. J., Curado, F., Somerville, E. N., Rennecke, J., Bauer, P., & Beetz, C. (2026). Data from the ROPAD study corroborate an association between ITSN1 loss-of-function variants and Parkinson’s disease. npj Parkinson's Disease, 12(1), Article 237. https://doi.org/10.1038/s41531-026-01562-x

Image Credits: AI Generated

DOI: 10.1038/s41531-026-01562-x

Keywords: Parkinson's disease, ITSN1, genetics, loss-of-function variants, ROPAD study, haploinsufficiency, Intersectin-1, neurodegeneration, exome sequencing, age at onset, GBA1, pleiotropy

The biological logic of STING makes such a map unusually valuable. Under normal conditions, STING resides in an inactive, self-inhibited conformation on the endoplasmic reticulum membrane, its ligand-binding domain held in a closed orientation. When cyclic dinucleotides, either bacterial second messengers or the mammalian cyclic GMP-AMP synthesized by the sensor cGAS after DNA leakage into the cytoplasm, bind to the ligand-binding pocket, STING rotates into an open state, exits the endoplasmic reticulum through the Golgi apparatus, and initiates a phosphorylation cascade through TBK1 and IRF3 that drives type I interferon and inflammatory cytokine production. The protein therefore operates as a conformational switch under tight negative control, and mutations that nudge the equilibrium in either direction produce distinctive disease phenotypes.

Gain-of-function variants of STING sit at one end of the clinical spectrum. Amino acid substitutions clustered in the dimerization interface and the lid region that covers the cyclic dinucleotide binding pocket destabilize the closed, inactive conformation, allowing spontaneous ligand-independent activation. Patients carrying such variants develop the autoinflammatory syndrome now classified as STING-associated vasculopathy with onset in infancy, or SAVI, characterized by systemic inflammation, interstitial lung disease, and vascular pathology that mirrors constitutive interferon signaling. Additional gain-of-function alleles have been linked to familial chilblain lupus and related interferonopathies, and mouse models carrying equivalent substitutions recapitulate the lethal inflammatory phenotype, confirming that the mutated protein itself, rather than an upstream sensing defect, drives pathology.

Loss-of-function variants occupy the opposite pole of the atlas. Biallelic inactivating mutations in the STING-encoding TMEM173 gene have been identified in patients presenting with a combined immunodeficiency marked by recurrent and severe viral infections, particularly respiratory viruses, alongside pulmonary disease. These alleles cluster in distinct structural neighborhoods: some disrupt ligand binding, others impair the conformational rearrangements needed for trafficking to the Golgi, and still others destabilize the protein so that steady-state abundance collapses. Intriguingly, a founder allele common in certain populations ablates STING function with apparently modest fitness cost, a reminder that evolutionary pressure from pathogens can shape the distribution of immune gene variants in ways that remain only partly understood.

Cancer adds a third interpretive layer to the mutation catalog. Tumors frequently acquire mutations that silence STING signaling, because intact STING activity, by recruiting and activating antigen-presenting cells within the tumor microenvironment, opposes immune evasion. Loss-of-function alterations of STING pathway components have been documented across a range of malignancies, including colorectal and gastric cancers, and correlate with diminished T-cell infiltration and poorer responses to immune checkpoint blockade. Conversely, pharmacological activation of STING with synthetic cyclic dinucleotide agonists has emerged as a major strategy in cancer immunotherapy, with numerous candidates advancing through preclinical and clinical evaluation. The atlas therefore serves a translational purpose: a clinician or drug developer can query whether a given tumor-associated substitution is predicted to ablate, enhance, or leave unaffected STING signaling, and can reason about how that functional assignment might inform immunotherapy selection.

What distinguishes a systematic atlas from a simple variant list is the integration of structural and biophysical annotation. High-resolution crystal and cryogenic electron microscopy structures of STING from human and multiple animal species have defined the ligand-binding pocket, the dimer interface, the hydrophobic lid, and the transmembrane segment, while molecular dynamics simulations have mapped the conformational transitions connecting inactive and active states. By projecting every cataloged missense mutation onto these structural ensembles, the resource makes mechanistic hypotheses explicit: substitutions can be classified by their proximity to the ligand pocket, their predicted effect on dimer stability, their likely influence on the trafficking sequence that shuttles STING from endoplasmic reticulum to Golgi, or their impact on the post-translational modification sites, including palmitoylation and phosphorylation, that modulate signaling intensity and duration.

The clinical translation dimension of the atlas extends beyond cancer. STING agonists are being explored as vaccine adjuvants and as treatments for chronic viral infections, where a transient burst of innate stimulation could strengthen adaptive immune responses. At the same time, excessive STING activation has been implicated in sterile inflammatory diseases, neurodegeneration, and aspects of aging biology, prompting the parallel development of STING inhibitors. An evidence-based map of how sequence variation alters STING function is directly relevant to both efforts, because it identifies which patient subgroups carry hypomorphic or hypermorphic alleles that could shift the therapeutic window. Precision dosing and patient stratification for STING-targeted drugs may ultimately depend on genotyping knowledge of exactly the kind this resource consolidates.

The methodological logic of atlas-building also deserves attention. Rather than relying on any single assay, the resource aggregates evidence from patient phenotypes, reporter assays measuring interferon promoter activation, protein localization studies, ligand-binding measurements, and animal models, assigning each variant a functional class supported by converging data. This convergence-based approach mitigates a chronic weakness of the field, in which individual studies using different cell lines and stimulation conditions have occasionally reported conflicting results for the same variant. By standardizing nomenclature, linking each entry to structural context, and flagging variants whose functional assignment rests on limited evidence, the atlas establishes a framework that future experimental work can extend systematically rather than idiosyncratically.

Several open questions frame the next phase of this effort. The functional consequences of many rare missense variants observed in large human sequencing cohorts remain untested, and the interplay between STING sequence variation and other innate immune genes, including cGAS itself and the downstream interferon receptor machinery, is only beginning to be explored. The pharmacological landscape is similarly incomplete: structural differences between human and rodent STING complicate the translation of agonists and inhibitors across species, and variants that alter drug binding pockets could produce patient-to-patient differences in treatment response. A living, continuously updated atlas offers a shared reference point for addressing these gaps, converting the accumulated knowledge of two decades of STING research into a practical instrument for genetic diagnosis, drug development, and, ultimately, the individualized treatment of the inflammatory, infectious, and malignant diseases in which this remarkable signaling protein sits at the center.

Subject of Research: Systematic functional and structural cataloging of STING protein mutations linked to autoinflammatory disease, immunodeficiency, and cancer immunotherapy

Article Title: Atlas-ing STING mutations to advance fundamental understanding and clinical translation

Article References: Zhang, B.-C., & Paludan, S. R. (2026). Atlas-ing STING mutations to advance fundamental understanding and clinical translation. Cell Research. https://doi.org/10.1038/s41422-026-01294-w

Image Credits: AI Generated

DOI: 10.1038/s41422-026-01294-w

Keywords: STING, innate immunity, TMEM173, SAVI, interferon signaling, cGAS, cyclic dinucleotides, loss-of-function variants, gain-of-function variants, cancer immunotherapy, STING agonists, autoinflammatory disease